“Thromboinflammation in COVID-19: can α2-macroglobulin help to control the fire?”: Comment from Seitz et al.

[1]  Rajnish K. Prasad,et al.  Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT , 2022, Circulation.

[2]  P. Ridker,et al.  Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status. , 2022, JAMA.

[3]  M. Levy,et al.  Reducing the global burden of sepsis: a positive legacy for the COVID-19 pandemic? , 2021, Intensive Care Medicine.

[4]  J. Berger,et al.  Anticoagulation in COVID-19: reaction to the ACTION trial , 2021, The Lancet.

[5]  Zekarias T. Asnake,et al.  COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation , 2021, Heart & Lung.

[6]  N. Mackman,et al.  Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19 , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[7]  L. Gürtler,et al.  Thromboinflammation in COVID‐19: Can α2‐macroglobulin help to control the fire? , 2020, Journal of Thrombosis and Haemostasis.

[8]  Kanika Jain,et al.  Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation , 2020, Nature Reviews Cardiology.

[9]  V. Cantaluppi,et al.  “War to the knife” against thromboinflammation to protect endothelial function of COVID-19 patients , 2020, Critical Care.

[10]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[11]  Mark R. Wilson,et al.  Alpha-2-Macroglobulin, a Hypochlorite-Regulated Chaperone and Immune System Modulator , 2019, Oxidative medicine and cellular longevity.

[12]  Christopher M. Dobson,et al.  Alpha-2-Macroglobulin Is Acutely Sensitive to Freezing and Lyophilization: Implications for Structural and Functional Studies , 2015, PloS one.